Literature DB >> 24746298

Syringocystadenocarcinoma papilliferum with locoregional metastases.

Elizabeth Satter1, Derek Grady, Caroline T Schlocker.   

Abstract

Syringocystadenocarcinoma papilliferum (SCACP) is a rare malignant counterpart of syringocystadenoma papilliferum (SCAP). To date, less than 30 cases have been reported, and of those, only three had locoregional metastases [1,2]. Herein, we report a case of a 42-year-old man with a rapidly growing nodule on his right parietal scalp ultimately diagnosed as SCACP arising in association with a preexisting SCAP and nevus sebaceus. This case differs from prior reports in the tumor's rapid growth and aggressive course with the development of locoregional metastases within 5-weeks from initial presentation.

Entities:  

Mesh:

Year:  2014        PMID: 24746298

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  4 in total

Review 1.  Somatic V600E BRAF Mutation in Linear and Sporadic Syringocystadenoma Papilliferum.

Authors:  Jonathan L Levinsohn; Jeffrey L Sugarman; Kaya Bilguvar; Jennifer M McNiff; Keith A Choate
Journal:  J Invest Dermatol       Date:  2015-05-07       Impact factor: 8.551

2.  Chemoradiotherapy in a Case of Malignant Syringocystadenocarcinoma Papilliferum of Vulva with Locoregional Failure.

Authors:  Pamidimukkala Bramhananda Rao; Saptarshi Ghosh; Manisha Mohapatra; N Pramod Philip; P Ravindra Kumar; Surendra Manam; Pradeep Karra; Vijay Krishna Jasti
Journal:  Case Rep Oncol Med       Date:  2015-11-30

3.  Syringocystadenocarcinoma papilliferum with orbital invasion: a case report with literature review.

Authors:  Carla Pagano Boza; Joaquin Gonzalez-Barlatay; Shoaib Ugradar; Melina Pol; Eduardo Jorge Premoli
Journal:  Ther Adv Ophthalmol       Date:  2019-04-26

4.  Syringocystadenocarcinoma Papilliferum: A Case Report and Review of the Literature.

Authors:  Kyoung Geun Lee; Won Choi; Joon Soo Lim; Hyung Jin Hahn; Ki Bum Myung; Seung Hyun Cheong
Journal:  Ann Dermatol       Date:  2019-08-30       Impact factor: 1.444

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.